Dr. Eisenhauer’s research has transformed the fields of cancer clinical trials and cancer drug delivery. Her fundamental contributions to the clinical evaluation of new anti-cancer agents, as well as cancer research strategy and clinical trials development, have been critical in the development of new treatments for ovarian cancer, malignant melanoma and brain tumours. She is credited with developing new methodologies for the delivery of Taxol, one of the most important cancer drugs in the world, which maintained the drug’s efficacy and reduced toxic side effects to cancer patients. This shorter, safer method to deliver the drug has become the international standard, transforming the experience and outcomes of millions of patients worldwide.
Dr. Eisenhauer’s extraordinary contributions extend to impactful national and international leadership roles including the founding in 1982 and subsequent direction of the Investigational New Drug Program (IND) of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG), now the Canadian Cancer Trials Group. Dr. Eisenhauer also co-led the Methodology for the Development of Innovative Cancer Therapies International Task Force where she developed recommendations for the design and endpoints for trials of novel targeted cancer agents. As well she led the creation of the first collaborative cancer research strategy for Canada in her role as co-Chair of the Canadian Cancer Research Alliance, convened the first Summit to create a Tobacco Endgame for Canada and was inaugural Expert Lead for Research in the Canadian Partnership against Cancer.
Dr. Eisenhauer’s commitment to the advancement of cancer therapy, supportive care and prevention is unparalleled. Her extensive research contributions and leadership within the field of cancer care in Canada have influenced and advanced the conduct of clinical trials internationally. Her work has expanded the understanding of therapeutic interventions and has led to new standards of cancer treatment for patients in Canada and around the world.